Navigation Links
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Date:3/27/2008

.com" target="_new">http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market for PEGINTRON and REBETOL. Forward-looking statements relate to expectations or forecasts of future events. Schering- Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering- Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering- Plough's Securities and Exchange Commission filings, including Part I, Item 1A. "Risk Factors" in Schering-Plough's 2007 10-K/A.

References:

(1) Jacobson IM, et al. Peginterferon alfa-2b and Weight-Based or Flat-

Dose Ribavirin in Chronic Hepatitis C Patients: A Randomized Trial.

Hepatology 2007; 46:971-981.

(2) p=0.01, primary efficacy comparison (based on data from subjects

weighing 65 kg or higher at baseline and utilizing a logistic

regression analysis that includes treatment [weight-based dose or flat

dose], genotype and presence/absence of advanced fibrosis, in the

model).

(3) Manns MP, et al. Peginterferon alfa-2b plus Ribavirin Compared with

Interferon alfa-2b plus Ribavirin for Initial Treatment of Chronic

Hepatitis C: A Randomized Trial. Lancet 2001;358:958-965.

(4) The IDEAL (Individualized Dosing Efficacy vs. Flat Dosing to Assess

<
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
4. Obesity-Related Hormone is Higher in Children with Down Syndrome
5. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
6. BSGI Posts Higher Sensitivity than Mammography or MRI for the Detection of Ductal Carcinoma In Situ
7. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
8. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
11. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...re/ -- New research has found that the availabilit...T) scanner in an emergency room can significantly ...a potentially life-saving treatment. Results of th...NSMC)-Salem Hospital in Salem, Mass., will be pres...cal Society of North America (RSNA). , , "T...
(Date:12/1/2008)...RNewswire-USNewswire/ -- A study has found that po... for imaging the breast, is not affected by either...factors that limit the effectiveness of standard m...ll be presented today at the annual meeting of the... , "The ability of PEM to detect cancer does...
(Date:12/1/2008)...irstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: ...f the world,s leading medical journals, results of... experimental compound tasimelteon (VEC-162). The...elatonin agonist tasimelteon (VEC-162) for transie... controlled multicentre trials." Results are repor...
(Date:12/1/2008)...rgeGen has announced that an oral,presentation of...d clinical,trial of TG101348 in myeloproliferativ... American Society of Hematology (ASH) Meeting. , ...:, Title: A Phase I Study of TG... JAK2-Selective Inhibitor, in Patients with,...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Helix BioPharma Announces 2411 4 Million Private Placement 7982 1Helix BioPharma Announces 2411 4 Million Private Placement 7982 2New England Peptide Names Director of Chemical Development 7977 1New England Peptide Names Director of Chemical Development 7977 2LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 1LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 2LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 3Kazak apple research key to preventing blue mold 5127 1Kazak apple research key to preventing blue mold 5127 2
...al Meeting of the American,Psychiatric Association... -- In adults with,major depressive disorder, addi...sulted in significant improvement in the primary,e...Scale (MADRS),Total Score. In this six-week, rando...the 160th Annual Meeting of the American,Psychiatr...
...ewswire/ -- Sirion Therapeutics,Inc., an ophthalm...day that it has received orphan drug designation f... anti-viral therapy,ganciclovir, for the treatmen...ently marketed by Laboratoires Thea in Europe unde... rights to,Virgan(R) for the United States from La...
Other Medicine Technology:Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2
(Date:12/2/2008)... At this year,s ASHP midyear meeting...rusted distributor of critical-care biopharmaceuti...model for supply chain integrity and demonstrate h...on to a new level. (Booth #1439) , ...,s ASHP midyear meeting, FFF Enterprises, the nati...
(Date:12/2/2008)... Marathon Health, a leading provider...s, has announced that New Balance, the athletic pr...velop, implement and manage onsite health clinics ...alance facilities in Maine , ...athon Health, a leading provider of onsite employe...
(Date:12/2/2008)... Does your over-the-phone interpreta... after you have completed the call? , ...2008 -- In the world of over-the-phone interpretat...OPI, a second over one minute can add up over the ...ding. When an organization employs an over-the-pho...
(Date:12/2/2008)... For many families, the problem with... Koch provides insight into how caregivers of agin...to the elder care experience. , ...or many families the stress of the holiday season ...t and elder care expert Esther Koch , founder of ...
Breaking Medicine News(10 mins):Health News:FFF Enterprises Unveils &#8216;The 8 Critical Steps to Guaranteed Channel Integrity' at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Orlando 2Health News:FFF Enterprises Unveils &#8216;The 8 Critical Steps to Guaranteed Channel Integrity' at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Orlando 3Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 2Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3
...troke victims to bust blood clots may help treat s... according to a study published Monday. While tre... significantly in the last 25 years, it has largel...tbite, say the authors of the article published in...
...f an unarmed man on his wedding day, the New York ...halyzer tests after such shootings. Sean Bell, a 2... girlfriend, died in a hail of 50 bullets hours be...ar. Police opened fire on Bells car outside a top...
...on for cancer patients who have to spend weeks in ...ase of Nick Gall-Tomassen, aged 31, suffering fro...on time away from the ward. His backpack holds re...t into his body through a vein in his arm. Nick sa...
... Heart Center helps explain excessive body weight ...body weight is associated with a thickening of the...mping chamber. Known to physicians as left ventric...can lead to heart failure and rhythm problems. &#...
Other Medicine News:Health News:Frostbite can Be Treated by Bloodclot Drug 2Health News:Breathalyzer Tests for Cops Involved in Shootings 2Health News:Special Backpacks Provide Much Needed Relief for Cancer Patients 2
Avant E-Z Rack Premium Low Binding 10 l Microreach Pipet Tips are accurate, contamination free, and allow quantitative transfer of your samples without relying on silicone.
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Medicine Products: